Deutsche Bank upgrades agilon health stock rating on raised guidance
Deutsche Bank upgraded agilon health Inc (NYSE:AGL) to Buy from Hold and raised its price target to $49.00 from $33.00, following the company's decision to raise its full-year guidance due to strong first-quarter results and higher risk score expectations. The company also saw a medical margin guidance increase and an adjusted EBITDA guidance rise, driven by better-than-expected risk scores and strong ACO REACH performance. Jefferies also recently upgraded Agilon Health's stock and increased its price target, citing improved trend visibility and supportive Medicare Advantage rates.
Law Offices of Frank R. Cruz Encourages agilon health, inc. (AGL)
The Law Offices of Frank R. Cruz has filed a class-action lawsuit against agilon health, inc. (AGL) on behalf of investors who purchased securities between February 26, 2025, and August 4, 2025. The lawsuit alleges that agilon health made materially false and misleading statements and failed to disclose adverse facts, leading to a significant stock price drop after the CEO's termination and the suspension of 2025 guidance. Investors have until March 2, 2026, to file a lead plaintiff motion.
Form 4 agilon health Inc For: 2 July By Investing.com
This article announces the filing of a Form 4 for agilon health Inc. on July 2nd. It is a brief announcement without further details, typical of an automated financial news update. The article also provides a general overview of market performance and other popular news headlines.
CFO of agilon health (AGL) uses 2,311 shares to cover RSU taxes
agilon health's Chief Financial Officer, Jeffrey A. Schwaneke, had 2,311 shares of Common Stock withheld by the company to satisfy tax obligations related to the net settlement of restricted stock units. This transaction was not an open-market sale. Following this withholding, Schwaneke directly holds 138,031 shares, which includes additional restricted stock units.
Can Agilon Health (AGL) Still Look Cheap, Or Is Hope Priced In?
Agilon Health (AGL) has seen a significant 563.5% gain year-to-date, prompting questions about its current valuation. Despite the sharp rise, Simply Wall St's analysis indicates the stock still screens as undervalued in multiple areas, particularly on a price-to-sales basis (P/S ratio of 0.3x compared to an industry average of 1.5x). The article suggests that while recent analyst upgrades and an improved outlook for value-based care contribute to optimism, investors must consider whether the current discount reflects genuine mispricing or a buffer for execution risks, especially concerning margins and Medicare Advantage exposure.
Price to sales forward of agilon health, inc. – NYSE:AGL
This article provides financial data for agilon health, inc. (NYSE: AGL), specifically focusing on its forward price-to-sales ratio. It indicates that the data is presented within the TradingView platform, noting the market status as closed.
3 Reasons AGL is Risky and 1 Stock to Buy Instead
The article discusses why agilon health (AGL) is considered a risky investment despite a significant recent stock increase. Key concerns include a declining customer base, projected revenue growth showing limited upside, and a negative free cash flow margin. The author suggests investors consider an alternative high-quality stock instead.
How Investors Are Reacting To agilon health (AGL) Upgraded Momentum And Rising Earnings Estimates
agilon health (AGL) has received a Momentum Style Score of B and a Zacks Rank of #2 (Buy), driven by upward revisions in earnings estimates for the current and next fiscal years. This improved sentiment stems from the company's value-based care model, raised 2026 revenue guidance, and strong Q1 2026 profitability, despite ongoing execution risks related to risk adjustment revenue and contract renewals. Investors are encouraged to consider diverse perspectives as analysts' views on future growth and profitability vary significantly.
Bronstein, Gewirtz & Grossman, LLC Encourages agilon health, inc. (AGL) Stockholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of agilon health, inc. (NYSE: AGL) securities. This investigation follows the announcement on August 4, 2025, that President and CEO Steven Sell was stepping down and the company withdrew its full-year 2025 financial guidance, causing a significant drop in Agilon's stock price. Investors who purchased Agilon securities are encouraged to contact the firm to assist with the investigation.
agilon health, inc. (AGL) Investigation: Bronstein, Gewirtz & Gro
Bronstein, Gewirtz & Grossman, LLC has initiated an investigation into agilon health, inc. (AGL) following the immediate stepping down of CEO Steven Sell and the withdrawal of the company's full-year 2025 financial guidance on August 4, 2025. This news led to a significant drop of over 27.2% in Agilon's stock price during after-hours trading. The law firm is encouraging shareholders who purchased Agilon securities to contact them to learn more about the investigation into potential claims.
AGL Jumps As agilon health Steps Up Outreach To Wall Street
Shares of agilon health (AGL) have risen significantly following increased outreach to Wall Street and positive sentiment on its value-based care growth. The company's management will attend upcoming healthcare conferences to boost investor engagement. Despite rapid top-line growth, AGL remains structurally loss-making, but technical analysis shows a sharp bullish inflection, with the stock breaking resistance levels.
AGL Stock Climbs As agilon health Steps Up Outreach
agilon health (AGL) stock climbed by 11.19% due to positive sentiment regarding its value-based care growth prospects. The company's management is increasing industry visibility and investor engagement by attending healthcare conferences. Despite strong revenue growth, AGL faces challenges with structurally negative margins and poor capital efficiency, though recent cash flow is positive.
Enterprise value to revenue forward of agilon health, inc. – NYSE:AGL
The article discusses the enterprise value to revenue forward for agilon health, inc. (NYSE: AGL). It provides financial data and links to various trading and market analysis tools provided by TradingView. The content primarily serves as a placeholder for financial metrics related to the company on the TradingView platform.
AGL Jumps As agilon health Steps Up Conference Push
Agilon health (AGL) stock climbed over 10% due to optimism surrounding expanded value-based primary care partnerships and upcoming presentations at healthcare conferences. While the company exhibits strong revenue growth and asset turnover, profitability remains negative, though Q1 2026 showed positive net income. Traders are advised to watch technical support levels around $106-$108 and resistance at $118-$120, with a long-term upside target of $125.
Agilon Health (AGL) Is Up 0.79% in One Week: What You Should Know
Agilon Health (AGL) has shown positive momentum, with its shares up 0.79% in the past week and 18.68% over the last month, significantly outperforming its industry and the S&P 500. The company holds a Zacks Momentum Style Score of B and a Zacks Rank of #2 (Buy), indicating strong potential. This performance is supported by positive earnings estimate revisions and robust price activity.
Enterprise value to EBIT forward of agilon health, inc. – BOATS:AGL
This article focuses on the enterprise value to EBIT forward ratio for agilon health, inc. (AGL). It presents a financial metric from the perspective of BOATS (Blue Ocean Alternative Trade System), a system related to TradingView. The content is primarily a data point about AGL's financial valuation.
Price to earnings forward of agilon health, inc. – BOATS:AGL
This article provides financial information for agilon health, inc. (AGL) on the Blue Ocean Alternative Trade System (BOATS). It specifically references the "Price to earnings forward" metric for the company. The content appears to be a stub or a data lookup page from a financial platform.
agilon health inc Actuals & Estimates (NYSE:AGL)
This article provides an overview of agilon health, inc. (NYSE: AGL) stock, including its current price, market capitalization, and performance trends. It also details financial estimates, actual earnings per share, revenue, and net income, along with analysts' future price forecasts and recommendations. The piece concludes with information on the company's financial reporting, employee count, EBITDA, and guidance on how to invest in AGL stock.
Citizens reiterates agilon health stock rating ahead of forum
Citizens reiterated a Market Perform rating on agilon health Inc (NYSE:AGL) ahead of their annual Healthcare Services Forum. The stock is currently trading at $111.73, close to its 52-week high, after a significant 537% surge in six months. The forum will focus on data leverage, clinical pathways, payer dynamics, and cost management, while recent Q1 2026 earnings for AGL significantly surpassed forecasts.
Is the Options Market Predicting a Spike in agilon health Stock?
The options market is showing high implied volatility for agilon health (AGL) stock, particularly with the Jul 17, 2026 $70 Call, suggesting investors anticipate a significant price movement. Despite the market's expectation of a big move, analysts currently rate agilon health as a Zacks Rank #3 (Hold), although recent earnings estimates for the current quarter have been revised upward. This combination of high implied volatility and improving analyst sentiment could indicate a potential options trading opportunity.
Agilon Health stock hits 52-week high at 118.47 USD By Investing.com
Agilon Health Inc. (AGL) reached a 52-week high of $118.47 USD, marking a 116% surge over the past year and 561% year-to-date. This growth follows a strong Q1 2026 report with EPS of $2.94 and revenue of $1.42 billion, driven by effective medical expense management. Analysts like Bernstein SocGen Group and Leerink have raised price targets, while Truist Securities maintains a Hold rating.
Barclays Upgrades Agilon Health (AGL)
Barclays upgraded Agilon Health (AGL) to Equal Weight from Underweight on May 26, setting a price target of $81 due to improved outlook for value-based care and stabilized cost trends. Benchmark also updated its rating on May 21, raising the price target to $95 from $13 and reiterating a Buy rating, citing the company's potential for dramatic margin expansion and accelerating growth. Agilon Health, Inc. provides healthcare services, and both firms recognize its long-term investment potential.
Barclays Upgrades Agilon Health (AGL)
Barclays has upgraded Agilon Health (AGL) from Underweight to Equal Weight, setting a price target of $81. This upgrade is driven by an improved outlook for value-based care, stabilizing cost trends, and a more favorable 2027 Medicare Advantage rate outcome. Benchmark also raised its price target for AGL to $95 from $13, reiterating a Buy rating, citing potential for dramatic margin expansion and accelerating growth.
Agilon Health stock hits 52-week high at 118.47 USD
Agilon Health (AGL) stock has reached a 52-week high of $118.25, reflecting a 116% surge over the past year and significant recent gains. The company's strong performance is supported by impressive Q1 2026 earnings, which surpassed forecasts, and positive adjustments to analyst price targets. Despite being in overbought territory according to the RSI, the stock is considered undervalued by InvestingPro's Fair Value assessment.
Agilon health, inc.(NYSE: AGL) added to S&P Health Care Services Select Industry Index
Agilon health, inc. (NYSE: AGL) has been added to the S&P Health Care Services Select Industry Index. This news follows a period of significant activity for the company, including recent upgrades by Jefferies and Deutsche Bank, and a reverse stock split. The company operates a Medicare-centric, capitated business model providing healthcare for seniors.
The Bull Case For agilon health (AGL) Could Change Following Diverging Earnings Hopes And Weaker Financials
Agilon health (AGL) has seen upward revisions in earnings estimates and improved analyst sentiment despite reporting weaker financials with declining year-over-year revenue. This creates a disconnect between investor expectations and current fundamentals, particularly given its reliance on a few major payer contracts and the recent 1-for-25 reverse stock split aimed at maintaining NYSE listing. The article raises questions about the sustainability of its investment narrative and risk profile.
agilon health inc (AGL) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of agilon health inc (AGL), listing its major shareholders and their proportional holdings. It also provides a breakdown of shareholder types and institutional shareholding data over several quarters, highlighting changes in shares held and proportion for top institutional investors.
agilon health inc (AGL) Dividends & Stock Splits: Historical Payouts and Event Timeline
The article provides a financial overview of agilon health inc (AGL), focusing on its dividend history and stock split events. It indicates that AGL has not distributed any dividends in the past five years and lists one stock split event: a 25-to
Agilon Health: agilon health, inc. - Reverse Split Option Symbol: AGL New Symbol: AGL1
This article announces a reverse stock split for Agilon Health, changing its option symbol from AGL to AGL1. This change is effective following the reverse split, indicating a corporate action affecting the company's shares and related options.
agilon health inc (AGL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article from TradingKey focuses on agilon health inc (AGL) and its revenue breakdown. However, it states that relevant data for business segments, regional revenue, and profit contribution have not yet been disclosed by the company. The page provides general stock information for AGL, including its current price, market cap, and links to other financial analysis tools.
agilon health inc (AGL) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for agilon health inc (AGL), highlighting its current earnings forecast score, analyst ratings, and price targets. It details expected revenue and EPS for upcoming quarters and compares AGL's analyst coverage with peers in the Healthcare Providers & Services industry. The forecast indicates a "Hold" trend based on 17 analysts, with a target price of USD 1.00.
When Will Agilon Health, Inc. (NYSE:AGL) Breakeven?
This article analyzes Agilon Health, Inc.'s path to profitability, focusing on analyst estimates for when the company is expected to break even and become cash flow positive. It delves into the average annual forecast loss, revenue growth expectations, and the factors contributing to the company's anticipated profitability by 2026.
agilon health to Participate in Upcoming Conferences
agilon health announced that members of its management team will attend two upcoming investor conferences in June 2026: the William Blair What's Next for Healthcare Distributors & Digital Health Conference in New York and the Citizens Healthcare Services Forum in Boston. The management team will participate in investor meetings, discussions, and a CEO Model panel at these events. Due to the format, meetings will not be webcast, but interested investors can contact the conference organizers or agilon health's Investor Relations team for registration information.
agilon health to Participate in Upcoming Conferences
agilon health (NYSE: AGL) announced that its management team will participate in two upcoming investor conferences in June 2026: the Truist Securities Healthcare Disruptors & Digital Health Conference and the Citizens Healthcare Services Forum. Management will engage in panel discussions and one-on-one meetings with investors, though these events will not be webcast. The company encourages interested parties to contact conference organizers or agilon health's Investor Relations for registration details.
agilon health inc stock (US00857U1079): shares among 2026’s high-flyers after massive year-to-date
Agilon Health Inc (AGL) has seen a dramatic surge in its share price in 2026, making it one of the year's top performers on the US market with a gain of over 400% and a market capitalization around USD 1.6 billion. The company operates a value-based primary care platform, partnering with physician groups to manage senior care, particularly Medicare Advantage populations, and generates revenue primarily through capitated arrangements with health plans. Its success is driven by managing medical costs effectively, expanding membership, and optimizing medical margins, though future performance will depend on consistent profitability and navigating regulatory and industry dynamics.
agilon health (AGL) CLO reports 485-share tax withholding, holds 66,112 shares
agilon health's Chief Legal Officer, Denise Zamore, reported a tax-related disposition of 485 shares. These shares were withheld by the company to cover income tax obligations stemming from the net settlement of restricted stock units and do not represent an open-market sale. Following this transaction, Zamore directly holds 66,112 shares, including restricted stock units.
Is agilon health's (AGL) Valuation Gap Overshadowing Deeper Questions About Leadership Stability?
Agilon health (AGL) is experiencing renewed investor interest due to a significant valuation gap highlighted by analysts, alongside a sharp share price rebound post-reverse split. However, this positive sentiment is tempered by concerns about leadership turnover, execution risks, ongoing securities lawsuits, and potential issues with medical cost control, particularly with a new CEO at the helm. The article suggests that despite the apparent undervaluation, these governance and operational challenges present significant short-term risks and catalysts for the company.
Agilon health Reports First Quarter 2026 Results
Agilon health, inc. (NYSE: AGL) announced strong first-quarter 2026 results, reporting total revenue of $1.42 billion and significantly increased net income of $49 million compared to the previous year. The company also raised its full-year 2026 guidance for total revenues, medical margin, and Adjusted EBITDA, attributing the performance to disciplined execution and strategic investments. Ronald A. Williams, Executive Chairman, highlighted progress in clinical execution and operating discipline, and welcomed Tim O'Rourke as the new CEO to further sharpen the focus on execution and stakeholder value.
Director Silvana Battaglia receives 2,133 RSUs at agilon health (AGL)
agilon health director Silvana Battaglia received an equity award of 2,133 restricted stock units (RSUs) on June 2, 2026, as reported in a Form 4 filing. These RSUs, granted at no cash cost, will vest in full on June 2, 2027, contingent upon her continued service as a director. Following this grant, her beneficial ownership stands at 7,926 shares, reflecting a 1-for-25 reverse stock split that became effective on March 30, 2026.
Director at agilon health (NYSE: AGL) receives grant of 2,133 RSUs
agilon health director Ronald A. Williams was granted 2,133 restricted stock units (RSUs) with a vesting date of June 2, 2027, provided he continues his service. After this grant, Williams beneficially owns 149,141 shares, a figure that accounts for the company's 1-for-25 reverse stock split effective March 30, 2026. This transaction is considered compensation-based and not an open-market trade.
Director at agilon health (AGL) receives 2,133-share RSU grant
agilon health director John William Wulf was granted 2,133 restricted stock units as compensation, which will vest in full on June 2, 2027, subject to his continued service. Following this grant, his beneficial ownership of agilon health shares, including RSUs, stands at 16,765, adjusted for a 1-for-25 reverse stock split effective March 30, 2026. This transaction reflects an equity award rather than an open-market stock purchase.
agilon health (AGL) director granted 2,133-share RSU award, now holds 8,207 shares
agilon health (AGL) director Karen McLoughlin was granted 2,133 restricted stock units (RSUs) on June 2, 2026. These RSUs will vest in full on June 2, 2027, provided she continues her service as a director. Following this award and accounting for a prior 1-for-25 reverse stock split, McLoughlin now beneficially owns a total of 8,207 shares, including the RSUs.
agilon health (NYSE: AGL) shareholders back directors, auditor and pay
agilon health (NYSE: AGL) stockholders approved all proposals at their annual meeting on June 2, 2026. Shareholders re-elected three Class II directors, ratified Ernst & Young LLP as the independent auditor for fiscal year 2026, and gave non-binding advisory approval to the compensation of named executive officers. These decisions were recorded in an 8-K filing outlining the voting results.
Agilon Health, Inc. Soars to New 52-Week High of $93.89
Agilon Health, Inc. (AGL) has reached a new 52-week high of $93.89, marking a 1,277.31% increase over the past year, significantly outperforming the S&P 500. Despite this impressive stock growth and a market capitalization of USD 247 million, the company remains unprofitable with a negative price-to-earnings ratio and return on equity. This milestone highlights its resilience within the pharmaceuticals and biotechnology sector.
Assessing agilon health (AGL) Valuation After A Sharp Share Price Rebound
agilon health (AGL) has seen a sharp share price rebound, with a 64.52% gain over the past year, prompting a re-evaluation of its valuation. While one narrative suggests the company is 371% overvalued with a fair value of $19.67 due to persistent losses, another analysis using a Discounted Cash Flow model indicates a steep discount with a fair value of $356.38 per share. Investors are urged to consider these conflicting valuations and key risks given the mixed picture on value and sentiment.
Agilon Health, Inc. Hits New 52-Week High of $93.84
Agilon Health, Inc. (AGL) has reached a new 52-week high of $93.84, representing a remarkable 1248.81% stock increase over the past year, significantly outperforming the S&P 500. Despite this impressive stock performance, the company remains unprofitable with a negative price-to-earnings ratio and return on equity, and maintains a market capitalization of $247 million with no dividend yield.
agilon health (AGL) CAO reports small RSU tax withholding, keeps 14,169 shares
agilon health's Chief Accounting Officer, Timothy Gertsch, reported a routine tax-related disposition of 8 shares of Common Stock at $86.39 per share to cover income tax obligations on vested restricted stock units. This transaction was a non-discretionary withholding, not an open-market sale, and he still directly holds 14,169 shares, including RSUs. The event is considered administrative housekeeping rather than a directional signal about the stock.
Does agilon health’s (AGL) Flat Near-Term Sales Outlook Undermine Its Value-Based Care Investment Story?
Agilon health (AGL) is facing increased scrutiny due to underwhelming customer growth, ongoing cash burn, and a projected flat sales outlook for the next 12 months. These concerns challenge the optimistic investment narrative surrounding its value-based care model for seniors. The article questions whether agilon health can sustainably scale its platform, especially after a recent 1-for-25 reverse stock split aimed at maintaining NYSE compliance.
Agilon Health stock hits 52-week high at 91.34 USD By Investing.com
Agilon Health's stock achieved a new 52-week high of $91.34, reflecting a significant 53% increase over the past year and over 413% in the last six months. The company reported strong Q1 2026 financial results, including an EPS of $2.94 and revenue of $1.42 billion, driving positive analyst target revisions. Despite the recent surge, InvestingPro analysis suggests the stock may still be undervalued.
Are medical stocks lagging Agilon Health (AGL) this year?
This article from MSN discusses whether medical stocks are underperforming compared to Agilon Health (AGL) this year. It specifically mentions Agilon Health, indicating a focus on its performance within the medical sector.
